Cerebrospinal fluid and PET biomarkers for in vivo diagnosis of posterior cortical atrophy as the early onset and focal variant of Alzheimer’s disease

2012 ◽  
Vol 7 (4) ◽  
pp. 403-407
Author(s):  
Pierre Krolak-Salmon ◽  
Alain Vighetto
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Early Onset ◽  
Cortical Atrophy ◽  
Posterior Cortical Atrophy ◽  
In Vivo Diagnosis

scholarly journals Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers

2013 ◽  
Vol 7 (1) ◽  
pp. 66-74 ◽  
Author(s):  
Leonardo Cruz de Souza ◽  
Maxime Bertoux ◽  
Aurélie Funkiewiez ◽  
Dalila Samri ◽  
Carole Azuar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cortical Atrophy ◽  
Csf Biomarkers ◽  
Post Mortem ◽  
Posterior Cortical Atrophy ◽  
Biological Profile ◽  
Atypical Presentations ◽  
Alzheimer Pathology

ABSTRACT Besides its typical amnesic presentation, focal atypical presentations of Alzheimer's disease (AD) have been described in neuropathological studies. These phenotypical variants of AD (so-called "atypical AD") do not follow the typical amnestic pattern and include non-amnestic focal cortical syndromes, such as posterior cortical atrophy and frontal variant AD. These variants exhibit characteristic histological lesions of Alzheimer pathology at post-mortem exam. By using physiopathological markers, such as cerebrospinal fluid markers, it is now possible to establish in vivo a biological diagnosis of AD in these focal cortical syndromes. We report a series of eight patients who were diagnosed with behavioural variant frontotemporal dementia based on their clinical, neuropsychological and neuroimaging findings, while CSF biomarkers showed an AD biological profile, thus supporting a diagnosis of frontal variant of AD.

scholarly journals Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use

2020 ◽  
Vol 10 (3) ◽  
pp. 116 ◽  
Author(s):  
Cristina d’Abramo ◽  
Luciano D’Adamio ◽  
Luca Giliberto
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
High Sensitivity ◽  
Brain Parenchyma ◽  
Metabolic Derangement ◽  
In Vivo Diagnosis ◽  
Definition Of ◽  
Sensitivity Specificity

Alzheimer’s disease (AD) is the most common type of dementia, affecting more than 5 million Americans, with steadily increasing mortality and incredible socio-economic burden. Not only have therapeutic efforts so far failed to reach significant efficacy, but the real pathogenesis of the disease is still obscure. The current theories are based on pathological findings of amyloid plaques and tau neurofibrillary tangles that accumulate in the brain parenchyma of affected patients. These findings have defined, together with the extensive neurodegeneration, the diagnostic criteria of the disease. The ability to detect changes in the levels of amyloid and tau in cerebrospinal fluid (CSF) first, and more recently in blood, has allowed us to use these biomarkers for the specific in-vivo diagnosis of AD in humans. Furthermore, other pathological elements of AD, such as the loss of neurons, inflammation and metabolic derangement, have translated to the definition of other CSF and blood biomarkers, which are not specific of the disease but, when combined with amyloid and tau, correlate with the progression from mild cognitive impairment to AD dementia, or identify patients who will develop AD pathology. In this review, we discuss the role of current and hypothetical biomarkers of Alzheimer’s disease, their specificity, and the caveats of current high-sensitivity platforms for their peripheral detection.

scholarly journals Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers

2018 ◽  
Vol 20 ◽  
pp. 1018-1025 ◽  
Author(s):  
Maxime Montembeault ◽  
Simona M. Brambati ◽  
Foudil Lamari ◽  
Agnès Michon ◽  
Dalila Samri ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cortical Atrophy ◽  
Posterior Cortical Atrophy ◽  
Cerebrospinal Fluid Biomarkers

O1-04-06: Elevated cerebrospinal fluid amyloid-Beta42 levels in young adults at genetic risk for early-onset alzheimer's disease

2011 ◽  
Vol 7 ◽  
pp. S102-S103 ◽  
Author(s):  
Eric Reiman ◽  
Carlos Velez-Pardo ◽  
Marelene Jimenez del Rio ◽  
Margarita Giraldo ◽  
Natalia Acosta-Baena ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Young Adults ◽  
Genetic Risk ◽  
Early Onset ◽  
Early Onset Alzheimer’S Disease

Difficulties in diagnosing atypical variants of Alzheimer’s disease

2021 ◽  
Vol 26 (5) ◽  
pp. 16-23
Author(s):  
A. A. Tappakhov ◽  
T. Ya. Nikolaeva ◽  
T. E. Popova ◽  
N. A. Shnayder
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Picture ◽  
Short Term Memory ◽  
Late Onset ◽  
Early Stage ◽  
Primary Progressive Aphasia ◽  
Cortical Atrophy ◽  
Posterior Cortical Atrophy ◽  
Short Term

Alzheimer’s disease (AD) is the most common cause of dementia in the population. Late onset AD has a classic clinical picture with short-term memory deficit, apraxia and agnosia. Patients with early-onset AD may have an atypical clinical picture which complicates diagnosis. Atypical AD variants include the logopenic variant of primary progressive aphasia, posterior cortical atrophy, behavioral, biparietal, and cortico-basal variants. These variants have pathomorphological signs similar to classical AD, but at an early stage they are characterized by focal atrophy which explains their clinical polymorphism. This article provides a review of the current literature on atypical types of AD and presents a clinical case of a 62-year-old patient in whom the disease debuted with prosopagnosia due to focal atrophy of the temporo-occipital regions of the non-dominant hemisphere.

O4-03-06: Effects of cortical visual impairment on navigational ability in posterior cortical atrophy and typical Alzheimer's disease

2015 ◽  
Vol 11 (7S_Part_6) ◽  
pp. P274-P274 ◽  
Author(s):  
Keir X.X. Yong ◽  
Catherine Holloway ◽  
Amelia Carton ◽  
Biao Yang ◽  
Tatsuto Suzuki ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Visual Impairment ◽  
Cortical Atrophy ◽  
Posterior Cortical Atrophy ◽  
Cortical Visual Impairment
Sign in / Sign up

Export Citation Format

Share Document